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Ultrafiltration is effective for treating fluid overload, but there
are no suitable machines for ambulatory treatment. This
study summarizes the use of a light-weight wearable
continuous ambulatory ultrafiltration device consisting of a
hollow fiber hemofilter, a battery operated pulsatile pump,
and two micropumps to control heparin administration and
ultrafiltration. Six volume-overloaded patients underwent
ultrafiltration for 6 h with treatment discontinued in one
patient due to a clotted catheter. Blood flow averaged
116 ml min1, the ultrafiltration rate ranged from
120–288 ml h1 with about 150 mmol of sodium removed.
Blood pressure, pulse, and biochemical parameters remained
stable with no significant hemolysis or complications. Our
data show that the wearable hemofilter appears to be safe,
effective, and practical for patients. This device could have a
major impact on the quality of life of fluid-overloaded
patients with heart failure. Additional studies will be needed
to confirm these initial promising results.
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The population affected by congestive heart failure (CHF)
continues to expand due to the epidemic growth in the
incidence of diabetes, obesity, coronary heart disease, and
diastolic dysfunction.1–3 The improved survival of patients
with ischemic heart disease and myocardial infarction fuels
further increments in this population. CHF New York Heart
Association (NYHA) class III and IV patients are a very
significant financial burden to US hospitals and the Medicare
program.4,5 CHF outcomes have improved somewhat with
the advent of both pharmacological advances including;
angiotensin-converting enzyme inhibitors, angiotensin
receptor blockers, natriuretic peptide analogues, diuretics,
b-blockers, vasopressin receptor blockers, and also the use of
pacemakers and implantable defibrillators.6–8 However,
despite these advances, the treatment of fluid overload and
sodium retention, which are the hallmarks of decompensated
CHF, remains problematical, and continues to cause
morbidity and hospitalization. These two complications are
exacerbated by neurohormonal disturbances and systemic
inflammation.9–11 In addition, aggressive diuretic adminis-
tration may worsen renal function, and thus increasing
mortality in these patients.12,13 Peritoneal and hemodialysis
have been advocated as useful treatments in severe cases of
CHF refractory to diuretic therapy.14,15 There is a growing
body of scientific literature supporting the notion that the
physical removal of fluid, cytokines and/or a myocardial
depressant factor by convection9 (that is, blood ultrafiltra-
tion) can significantly improve patient outcomes, and both
shorten hospital inpatient stays and intensive care unit
utilization.16–22 However, current ultrafiltration methods
require the use of stationary and bulky devices, reliant on
mains electricity supply, which do not allow prolonged or
continuous ultrafiltration. In addition, such acute hemofil-
tration treatments performed over 4–6 h, although efficient
and capable of removing up to 23 l of ultrafiltrate in a single
session23 are not physiological, and can potentially result in
major shifts of fluid from the intravascular compartment,
leading to hypotension, and hemodynamic instability.
Furthermore, they do not provide for a steady removal of
excess fluid and sodium.
A small wearable device that allows ambulatory hemofil-
tration to be performed in a slow and continuous fashion
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could afford patients the possibility of eliminating acute
hemodynamic changes and the freedom from spending many
hours attached to large stationary ultrafiltration machines
currently used for continuous renal replacement therapies.
This is not a new concept, as the first attempts to provide
such continuous treatments, date back more than 30 years
ago, to the pioneering reports by Kolff.24 We have previously
described the feasibility, safety, and efficacy of the wearable
artificial kidney (WAK),25 as well as its use as an ultrafiltra-
tion device, in animal studies.26 This device might not
only potentially contribute to improve the quality of life
and reduce the mortality of the ever-growing CHF
population, but also make these therapies more affordable
and reduce the financial burden incurred in treating
this condition. This study describes the first human use of
a wearable hemofiltration device (Figure 1) to manage fluid
overload. As such, this was a preliminary study, designed as
proof of concept, and also to assess both patient tolerability
and safety.
RESULTS
Six patients with fluid overload successfully underwent
hemofiltration using a wearable ultrafiltration device. Patient
and treatment parameters are outlined in Tables 1–4. The
hourly amount of ultrafiltration fluid removed ranged from
120 to 288 ml h1. The amount of ultrafiltrate was measured
both by volume and weight and corresponded to the rate of
removal indicated by the pump. The average ultrafiltration
rate was 192±68.3 ml h1, with a mean total ultrafiltrate
volume of 1084.33±335 ml. The average blood flow was
116±11 ml min1. Patient weights fell from 77.7 to 76.2 kg,
despite patients being encouraged to eat and drink.
The total amount of sodium removed was 150.7±
46.5 mmol. The pretreatment serum sodium was
137.3±3.1 mmol l1, and did not significantly change during
treatment, being 138±4.0 mmol l1 after 3 h and 139±
3.6 mmol l1 after 6 h of treatment. Similarly, the pretreat-
ment serum potassium was 5.1±1.0 mmol l1 and did not
change, being 5.1±0.9 mmol l1 at the end of the study. The
sieving coefficients for creatinine and urea were 0.98±0.02
and 0.96±0.05, respectively. The mean urea and creatinine
clearances were 3.1±0.9 and 3.2±1.0 ml min1, respectively.
There were no significant changes in heart rate, respiratory
rate, and/or temperature during the 6 h of ultrafiltration
treatment. There was a marginal, but significant decrease
in mean arterial pressure from 109.4±18.5 to 101.8±
17.3 mm Hg (Po0.03) (Table 3).
There were no changes in ECG pre- and posttreatment
with the hemofiltration device, and no observed arrhythmias
or changes in oxygen saturation. As fluid was successfully
removed, the hematocrit did increase after both 3 and 6 h of
treatment (Table 4). There was a modest but significant fall in
the peripheral platelet count. As with the hematocrit, there
was a marginal increase in serum lactate dehydrogenase. This
was probably due to a plasma volume effect rather than
significant hemolysis.
Initially, all patients were treated when lying down on a
bed, but during the study, all patients that so desired got out
of bed and walked around (Figure 2). There were no
technical complications or untoward effects, in terms of
blood pump malfunction, disconnections, and/or ultrafiltra-
tion/heparin pump errors. However, in one patient treatment
had to be terminated after 4 h due to a clotted catheter. All
patients were favorably impressed with the treatment, and no
patient made any complaints. During the study, patients were
encouraged to be ambulatory, eat and drink, so as to try and
simulate ordinary daily activity, while being connected to the
wearable hemofiltration device.
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Figure 1 | Diagram of the wearable hemofilter.
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DISCUSSION
Although the wearable hemofiltration device was designed as
a potential treatment for patients with refractory cardiac
failure, NYHA class IV, as this was the first-ever human study,
we elected to choose established hemodialysis patients, for
this proof of concept pilot trial. Established hemodialysis
patients were chosen, as they had already had established
central venous access catheters, used unfractionated heparin
for their routine hemodialysis treatments, and were volume
overloaded, as referenced to their known postdialysis target
weight.
In this initial proof of concept pilot study, six fluid-
overloaded patients underwent ambulatory hemofiltration
safely and effectively. Patients were encouraged to walk
around, eat, and perform some of the tasks of daily living to
assess the portability and comfort of the device. This first-
ever human study of a wearable artificial hemofiltration
device indicates that its application as such is feasible. The
preliminary data on the safety of the wearable hemofiltration
device is that the six patients showed no symptoms or signs
of complications. Blood pressure and heart rate did not
significantly change during hemofiltration. As expected,
during ultrafiltration, the hematocrit increased marginally,
although significantly. There was a minor but significant
change in peripheral platelet count. Although the serum
lactate dehydrogenase levels did increase slightly, this was
most likely, due to the reduction in plasma water, rather than
any significant hemolysis during treatment.
As this was a hemofiltration device, primarily designed to
treat patients with refractory heart failure, the amounts of
urea and creatinine removed were less than that during
comparable dialysis.
The preliminary data supporting the efficacy of the
wearable hemofiltration device showed that the volumetri-
cally controlled ultrafiltrate removal was accurate, according
to the amounts programmed into the built in control system,
over a wide range of volumes, from 120 to 288 ml h1 with an
accuracy of ±6%. There were no operational difficulties or
technical complications during the study, thus confirming
the results we obtained in previous animal studies.25,26
The wearable hemofiltration device was shown in this
proof of concept study to be an effective tool for the removal
of excess sodium. A total 150.7±46.5 mmol of sodium was
removed during this pilot study. If this was to be scaled up to
24 h sodium loss, this would equate to approximately
634 mmol (which is equivalent to 37 g of sodium chloride).
Patients with refractory cardiac failure are encouraged to eat
a low-sodium diet, typically restricting dietary salt intake to 2
or 3 g day1. This sodium loss is much greater than urinary
sodium losses that were achieved by simple loop diuretics,
and could potentially allow patients to have a less restricted
diet, with improvement in both terms of intake of food and
quality of life.
As this wearable device was designed as a hemofilter, the
absolute removal of urea and creatinine were much less than
that during a standard hemodialysis treatment. It may be
possible to add a dialysate component to the circuit to
Table 2 | Treatment characteristics of the wearable hemofiltration device
Patient no. Qb (ml min1) QUF (ml h
1) Heparin (IU h1) Rx time (h) Final aPTT (s) SC urea SC creatinine
1 134.2 120 758.3 6 107 1.00 0.97
2 118.9 288 300 4 49 0.96 0.98
3 121.9 120 1000 6 150 0.93 0.96
4 106.1 250 500 6 60 0.88 0.96
5 106.8 175 533.3 6 72 1.00 1.01
6 108.6 200 1000 6 137 1.00 1.01
Mean 116.1 192.1 681.9 5.7 95.8 0.96 0.98
s.d. 11.1 68.3 286.1 0.8 41.9 0.05 0.02
Shows blood flow (Qb), ultrafiltration rate (QUF), duration of treatment (Rx time), activated partial thromboplastin time (aPTT), and sieving coefficients (SCs) for urea and
creatinine.
Table 3 | Patient parameters during treatment with the wearable hemofiltration device
Patient no. 1 2 3 4 5 6 Mean±s.d. P-value
MAP mm Hg pre-UF 119.0 111.0 90.3 88.3 138.0 109.7 109.4±18.5
MAP mm Hg post-UF 87.3 111.0 98.7 76.7 120.0 117.0 101.8±17.3 0.03
Total UF (ml) 770 984 708 1610 1233 1201 1084.3±335.4
NaUF (mmol) 107.8 132.8 97.0 223.8 172.6 171.7 150.0±47.6
Shows mean arterial pressure (MAP), volume ultrafiltered (UF), and sodium removed in ultrafiltrate (NaUF). Data expressed as mean±s.d.







1 Male 50 Hypertension 6
2 Male 68 Diabetes 1
3 Male 68 Glomerulonephritis 108
4 Female 41 Polycystic kidneys 29
5 Male 42 Polycystic kidneys 2
6 Male 84.6 Hypertension and
diabetes
20
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improve solute clearances, but this would require a sorbent
system to adsorb solutes.25 Other workers are similarly trying
to develop a wearable dialysis device that does not require
any additional dialysate using nanotechnology.27
The wearable hemofiltration device requires extracorpor-
eal anticoagulation. For this initial proof of concept trial,
unfractionated heparin was chosen, as the participants were
regularly heparinized for their routine hemodialysis treat-
ments. As such, the heparin dose used for each patient was
empirically based on their previous hemodialysis treatments.
No patient suffered bleeding, although one patient had the
treatment terminated after 4 h due to catheter clotting, as the
activated partial thromboplastin time had fallen toward its
normal range. Further trials are required to determine
heparin requirements for extended treatments, and poten-
tially other anticoagulants might be used.
For this proof of concept initial trial, the wearable
hemofiltration device was assembled on a belt worn around
the abdomen. The proposed blood access for standard future
application during prolonged treatment would be a double-
lumen central venous catheter, tunneled under the skin, and
exiting at the level of the waist. Double cuffs would be placed
on the catheter to generate a mechanical barrier to potential
tunnel infection. Although we would prefer the vascular
access described above, other types of access may be used by
treating nephrologists, as experience with the wearable
hemofiltration device accumulates.
There is a growing body of literature supporting the
concept that blood ultrafiltration is an effective therapy for
the treatment of refractory fluid-overloaded patients with
CHF, and other hypervolemic states.16–22 In addition,
ultrafiltration has been shown to improve cardiac function
without deterioration of renal function in CHF patients, in
contrast to the deleterious effects of diuretics on glomerular
filtration rate,12,13,28,29 and in some cases, renal function
actually may be improved.30 Changes in serum creatinine
from o2 to 42 mg per 100 ml, in patients with CHF, have
been recently associated with a doubling in mortality.31,32
Thus, a significant reduction in the use of diuretics, which is
known to decrease the glomerular filtration rate and increase
serum creatinine, would hopefully be beneficial in preventing
worsening azotemia resulting from massive diuretic use, and
hopefully, reduce mortality. Ultrafiltration has been shown to
have significant beneficial effects in the electrolyte and
neurohormonal derangements associated with refractory
heart failure33 and allows for the avoidance of excessive and
ineffective diuretic treatment that is so often conducive to
renal failure, hypotension, and further metabolic complica-
tions. This contention is supported by the UNLOAD trial,
which has recently reported that ultrafiltration safely
produced greater weight and fluid loss than intravenous
diuretics, and in addition, reduced the 90-day health-care
resource utilization and treatment costs for patients with
decompensated heart failure.34
Until now, ultrafiltration could only be accomplished with
stationary dialysis machines or ultrafiltration devices that are
not amenable to be worn on the patient’s body and used
continuously while the patient is ambulatory. To our
knowledge, there is no other device available in the
therapeutic arsenal to potentially treat ambulatory patients
with continuous ultrafiltration. In comparing the wearable
hemofiltration device to those machines currently used for
hemofiltration, the WAK weights less than 2.5 pounds
(1.135 kg), requires a standard 9-V battery and adapts
ergonomically to the body contour, allowing wearability,
Figure 2 | A patient ambulating while undergoing treatment with
the wearable hemofilter.
Table 4 | Patient hematocrit (Hct), peripheral platelet count,
and lactate dehydrogenase (LDH)
Hct (%) Platelet (109 l1) LDH (U l1)
Patient
no. 0 h 3 h 6 h 0 h 3 h 6 h 0 h 3 h 6 h
1 38.9 39.6 39.1 221 197 212 427 458 457
2 23.1 23.5 23.1 235 203 227 658 680 670
3 31.2 31.6 32.8 147 110 105 198 261 271
4 32.9 34.2 34.3 105 110 107 220 279 309
5 41.1 42.1 43.1 210 197 177 348 413 470
6 28.7 31.7 31.0 236 249 237 350 415 407
Mean 32.65 33.8 33.9 192.3 177.7 177.5 366.8 417.7 430.7
s.d. 6.6 6.6 6.9 53.9 55.9 59 166.8 151.2 141.7
P-value 0.031 0.031 0.031 0.031 0.035 0.031 0.031 0.031 0.031
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with minimal interference to the activities of daily life. In
contrast, currently used machines are heavy, require a mains
electrical power source, and cannot be worn on the body,
thus impeding the ability of the patient to move around and
conduct activities of daily life while undergoing treatment.
Current machines, allow only for the removal of large,
unphysiological amounts of fluid in relatively short periods.
This, in turn, can lead to adverse hemodynamic changes.
Although the wearable hemofiltration device is unlikely to
cause this, as the rate of fluid removal is of similar magnitude
to urine output, and the blood flow necessary to achieve
these results of approximately 50–120 ml min is lower than
that of most commonly used hemofiltration and/or dialysis
machines. The fundamental characteristics of the device are
the lightweight, small size, and wearability.
The clinical significance of the wearable hemofiltration
device is the potential to reduce the incidence of acute
pulmonary edema, ascites, and other stigmata in patients
with NYH class III and IV CHF. Hopefully, further
development of this technique will lead to the introduction
of this therapy for patients with diuretic refractory heart
failure, and reduction in both morbidity and mortality. If
further clinical trials confirm the effectiveness and safety of
this device, then the economic impact in terms of the
reduction in length of hospital stay, ICU utilization and drug
consumption, as well as the number of hospital admissions
could potentially be considerable.
MATERIALS AND METHODS
The study was conducted at Ospedale San Bortolo, Vicenza, Italy
after approval by the Internal Bioethical Committee as provided in
the Declaration of Helsinki Principles.
As this was the first use in humans, and a proof of concept study,
patients with chronic kidney disease established on regular
hemodialysis, using a central venous dual lumen access catheter
for blood access, were recruited. These patients were chosen rather
than those with CHF, as they already had established venous access
and were regularly given heparin for extracorporeal anticoagulation.
Six patients volunteered for the study (Table 1). At the time of the
study, all patients were above their regular dry weight determined
for dialysis, the degree of fluid overload, ranging from 0.7 to 4.3 kg.
After obtaining appropriate informed consent, the venous access
catheter was connected to the wearable hemofiltration device, and
hemofiltration was performed in six patients. Five patients were
treated for 6 h and one patient was treated for only 4 h when
treatment had to be discontinued due to a clotted catheter. The
wearable artificial hemofiltration device (Xcorporeal Inc., Los
Angeles, CA, USA) comprised a standard commercially available
high flux hemofilter (Medica, Medolla, Italy), made of polysulfone
(inner diameter 250 microns, 2500 hollow fibers, 0.25 m2). A
specially designed pulsatile blood pump, that used a standard 9-V
battery as the energy source, and 2 micropumps (Sorenson, West
Jordan, UT, USA), one for heparin administration and another to
control the amount of ultrafiltrate removed (Figure 1). The total
weight of the device was 2.5 lb (1.135 kg).
The amount of unfractionated heparin infused ranged from
300 to 1000 IU h1, (Table 2) and was based on the usual amount
of heparin administered during their routine hemodialysis,
then adjusted according to activated partial thromboplastin
time.
The safety features of this wearable device included a
servomechanism with a bubble detector sensor placed after the
blood pump, designed to stop blood flow if air bubbles were
detected in the blood circuit, a second servomechanism that would
halt the ultrafiltration pump if the blood flow stopped for any
reason. In addition, the pulsatile blood pump had a self-limited
capacity to generate negative pressure for suction from the arterial
side of the catheter such that significant negative pressures could not
be applied to the vascular access. Similarly, on the venous side of the
circuit, any increased venous resistance would lead to cessation of
the blood pump. In the event of clotting within the circuit, the
changes in pressure would cause the blood pump to stop.
Blood flow was independently measured using an external
separate flow meter (Transonic Systems, Ithaca, NY, USA). At the
end of the treatment, all blood was returned to the patient and the
device disconnected. During the ultrafiltration treatment, pulse,
respiratory rate, blood pressure, and temperature were recorded at
regular intervals. In addition, electrocardiograms were recorded pre-
and posttreatment, and during the study, patients were monitored
with pulse oximetry and cardiac monitoring (Accutorr plus;
Datascope GmbH, Bensheim, Germany). The ultrafiltration rate
for each individual patient was determined, after both clinical
assessment of the degree of hypervolemia, and comparing pre-
ultrafiltration weight with the known postdialysis target weight.
Blood samples were taken from a sampling port in the blood tubing
of the device and corresponding ultrafiltrate samples obtained as
ultrafiltrate exited the filter at the beginning, after 3 h, and then at
the end of the treatment. During treatment patients were
encouraged to have lunch, drink fluids freely, and ambulate at their
leisure.
Statistical analysis
Data were analyzed using Prism software (GraphPad, San Diego,
CA, USA). The Wilcoxon signed-rank test was performed, and
Po0.05 was considered significant.
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